A phase i pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer

Clinical and Experimental Medicine

Volumn 12, Issue 3, 2012, Pages 173-180

  Rong, Yefei ^a   Qin, Xia ^b   Jin, Dayong ^a   Lou, Wenhui ^a   Wu, Lili ^b   Wang, Dansong ^a   Wu, Wenchuan ^a   Ni, Xiaolin ^a   Mao, Zhengfa ^a   Kuang, Tiantao ^a   Zang, Ying Qin ^c   Qin, Xinyu ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Dendritic cell; Immunotherapy; MUC1; Pancreatic cancer

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANZYME B; MUCIN 1;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL INFECTION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL THERAPY; CLINICAL ARTICLE; DRUG PULSE THERAPY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; ERYTHEMA; FEMALE; FEVER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL MONITORING; IMMUNOREACTIVITY; MALE; METASTASIS; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RECURRENT CANCER;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GRANZYMES; HUMANS; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRADERMAL; INTERFERON-GAMMA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUCIN-1; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PEPTIDES; PHENOTYPE; PILOT PROJECTS; VACCINATION;

EID: 84865476248     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-011-0159-0     Document Type: Article

References (26)

1. A Jemal T Murray E Ward A Samuels RC Tiwari A Ghafoor EJ Feuer MJ Thun 2005 Cancer statistics CA Cancer J Clin 55 1 10 30 15661684 10.3322/canjclin.55. 1.10
2. Ries L, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg LX, Mariotto A, Feuer EJ, Edwards BK (2006) SEER cancer statistics review, 1975-2003. Bethesda. National Cancer Institute, MD
3. AS Takhar P Palaniappan R Dhingsa DN Lobo 2004 Recent developments in diagnosis of pancreatic cancer BMJ 329 7467 668 673 15374918 10.1136/bmj.329.7467.668
4. L Donghui X Keping W Robert JL Abbruzzese 2004 Pancrea.tic cancer Lancet 363 9414 1049 1057 10.1016/S0140-6736(04)15841-8
5. TA Sohn CJ Yeo JL Cameron L Koniaris S Kaushai RA Abrams PK Sauter J Coleman RH Hruban KD Lillemoe 2000 Resected adenocarcinoma of the pancreas -616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 6 567 579 11307091 10.1016/S1091-255X(00)80105-5 1:STN:280:DC%2BD3Mzlt1yqtA%3D%3D
6. RA Abrams 2003 Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985? Int J Radiat Oncol Biol Phys 56 Suppl 4 3 9 12826245 10.1016/S0360-3016(03)00451-6
7. JP Neoptolemos DD Stocken H Friess C Bassi JA Dunn H Hickey H Berger L Fernandez-Cruz C Dervenis F Lacaine, et al. 2004 A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer N Engl J Med 350 12 1200 1210 15028824 10.1056/NEJMoa032295 1:CAS:528: DC%2BD2cXit12rtr8%3D
8. Y Kotera JD Fontenot G Pecher RS Metzgar OJ Finn 1994 Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients Cancer Res 54 11 2856 2860 7514493 1:CAS:528:DyaK2cXktVKqsbs%3D
9. G Pierre V Jenny Z Laurence C Théry S Amigorena 2002 Antigen presentation and T cell stimulation by dendritic cells Annu Rev Immunol 20 621 667 10.1146/annurev.immunol.20.100301.064828
10. CG Figdor IJ de Vries WJ Lesterhuis CJ Melief 2004 Dendritic cell immunotherapy: mapping the way Nat Med 10 5 475 480 15122249 10.1038/nm1039 1:CAS:528:DC%2BD2cXjsF2jtLs%3D
11. R Lau F Wang G Jeffery V Marty J Kuniyoshi E Bade ME Ryback J Weber 2001 Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma J Immunother 24 1 66 78 11211150 10.1097/00002371-200101000- 00008 1:CAS:528:DC%2BD3MXps1ajsQ%3D%3D
12. A Toubaji M Achtar M Provenzano VE Herrin R Behrens M Hamilton S Bernstein D Venzon B Gause F Marincola SN Khleif 2008 Pilot study of mutant Ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers Cancer Immunol Immunother 57 9 1413 1420 18297281 10.1007/s00262-008- 0477-6 1:CAS:528:DC%2BD1cXnsFeis70%3D
13. AE Chang BG Redman JR Whitfield BJ Nickoloff TM Braun PP Lee JD Geiger JJ Mulé 2002 A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer Clin Cancer Res 8 4 1021 1032 11948109 1:CAS:528:DC%2BD38XjsF2lsbY%3D
14. G Pecher A Häring L Kaiser E Thiel 2002 Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial Cancer Immunol Immunother 51 11-12 669 673 12439613 10.1007/s00262-002-0317-z 1:CAS:528:DC%2BD38XovVSlsbc%3D
15. B Jacques AK Palucka 2005 Dendritic cells as therapeutic vaccines against cancer Nat Rev Immunol 5 4 296 306 10.1038/nri1592
16. W Asavaroengchai MuleJJ KoteraY 2002 Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery Proc Natl Acad Sci USA 99 2 931 936 11792864 10.1073/pnas.022634999 1:CAS:528:DC%2BD38Xht1Wisbw%3D
17. MA Hollingsworth BJ Swanson 2004 Mucins in cancer: protection and control of the cell surface Nat Rev Cancer 4 1 45 60 14681689 10.1038/nrc1251 1:CAS:528:DC%2BD3sXpvVGnu7w%3D
18. BE Loveland A Zhao S White H Gan K Hamilton PX Xing GA Pietersz V Apostolopoulos H Vaughan V Karanikas, et al. 2006 Mannan-MUC1 pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma Clin Cancer Res 12 3 869 877 16467101 10.1158/1078-0432.CCR-05-1574 1:CAS:528: DC%2BD28XhtFeiu78%3D
19. MA Morse RE Coleman G Akabani N Niehaus D Coleman HK Lyerly 1999 Migration of human dendritic cells after injection in patients with metastatic malignancies Cancer Res 59 1 56 58 9892184 1:CAS:528:DyaK1MXmsFOhsA%3D%3D
20. LA Lambert GR Gibson M Maloney B Durell RJ Noelle RJ Barth 2001 Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity Cancer Res 61 2 641 646 11212262 1:CAS:528:DC%2BD3MXht1Gmsbs%3D
21. L Fong D Brockstedt C Benike L Wu EG Engleman 2001 Dendritic cells injected via different routes induce immunity in cancer patients J Immunol 166 6 4254 4259 11238679 1:CAS:528:DC%2BD3MXitVGmt70%3D
22. FO Nestle S Alijagic M Gilliet Y Sun S Grabbe R Dummer G Burg D Schadendorf 1998 Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat Med 4 3 328 332 9500607 10.1038/nm0398-328 1:CAS:528:DyaK1cXhs1Kisrc%3D
23. F Lawrence GE Edgar 2000 Dendritic cells in cancer immunotherapy Annu Rev Immunol 18 245 273 10.1146/annurev.immunol.18.1.245
24. RJ Barth JJ Mule PJ Spiess SA Rosenberg 1991 Interferon γ and tumor necrosis factor have a role in tumor regression mediated by murine CD8+ tumor-infiltrating lymphocytes J Exp Med 173 3 647 658 1900079 10.1084/jem.173.3.647 1:CAS:528:DyaK3MXhsVWht7k%3D
25. M Nagoshi PS Goedegebuure UL Burger N Sadanaga MP Chang TJ Eberlein 1998 Successful adoptive cellular immuno-therapy is dependent on induction of a host immune response triggered by cytokine (IFN-γ and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes J Immunol 160 1 334 344 9551989 1:CAS:528:DyaK1cXhtFWnuw%3D%3D
26. JW Heusel RL Wesselschmidt S Shresta JH Russell TJ Ley 1994 Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells Cell 76 6 977 987 8137431 10.1016/0092-8674(94)90376-X 1:CAS:528:DyaK2cXisVantbY%3D